Previous Article | Next Article 
Journal of Virology, April 2005, p. 5142-5152, Vol. 79, No. 8
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.8.5142-5152.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
A Peptide Pertaining to the Loop Segment of Human Immunodeficiency Virus gp41 Binds and Interacts with Model Biomembranes: Implications for the Fusion Mechanism
Roberto Pascual,
Miguel R. Moreno, and
José Villalaín*
Instituto de Biología Molecular y Celular, Universidad "Miguel Hernández," Elche-Alicante, Spain
Received 24 August 2004/
Accepted 5 November 2004

ABSTRACT
The human immunodeficiency virus gp41 envelope protein mediates
the entry of the virus into the target cell by promoting membrane
fusion. In order to gain new insights into the viral fusion
mechanism, we studied a 35-residue peptide pertaining to the
loop domain of gp41, both in solution and membrane bound, by
using infrared and fluorescence spectroscopy. We show here that
the peptide, which has a membrane-interacting surface, binds
and interacts with phospholipid model membranes and tends to
aggregate in the presence of a membranous medium and induce
the leakage of vesicle contents. The results reported in this
work, i.e., the destabilization and fusion of negatively charged
model membranes, suggest an essential role of the loop domain
in the membrane fusion process induced by gp41.

INTRODUCTION
Human immunodeficiency virus (HIV) is the causative agent of
AIDS, which acts by killing the CD4 T cells of the host organism
(
15,
23,
32,
47). Membrane fusion, i.e., the attachment and
consequent fusion of viral and cellular membranes, is mediated
by envelope glycoproteins located on the outer surface of the
viral membrane. The HIV surface glycoprotein is initially synthesized
as a highly glycosylated precursor, gp160, which is later cleaved
endoproteolytically by one cellular convertase into the surface
protein gp120, which determines viral tropism through the cellular
surface receptors, and the transmembrane protein gp41, which
is responsible for the membrane fusion process. Both gp120 and
gp41 remain noncovalently associated and supposedly trimeric
in their native prefusogenic state (
15,
23).
The native state of the HIV gp41 envelope protein is thought to be metastable by interacting with gp120 (32). For fusion and mixing of the viral and cellular contents to occur, gp41 must undergo a complex series of conformational changes, apparently triggered by the attachment of gp120 to CD4 and chemokine receptors of the target cell (13). It is thought that gp41 catalyzes membrane fusion through the induction of transient nonlamellar structures at the point where both bilayers merge (15, 23). The gp41 sequence is highly conserved and contains different functional regions within its ectodomain that are critical for membrane fusion (Fig. 1). A stretch of about 15 hydrophobic residues, named the fusion peptide (FP) and located at the N terminus of gp41, is believed to insert into and destabilize the membrane, thus facilitating viral and cell membrane fusion (4, 21). Consecutive to the FP, two heptad repeat regions, NHR and CHR, have been identified (22). Another essential segment for gp41-mediated fusion is the Trp-rich pretransmembrane domain (PTM) linking the CHR to the membrane-embedded anchor, TM (44). In the absence of lipid membranes, three NHR molecules fold into a central parallel triple-stranded
-helical coiled coil, with an outer layer of three antiparallel CHR
-helices wrapped antiparallel on the outside of this core and with each pair of NHR and CHR molecules connected by an immunogenic, protease-sensitive loop that reverses the polypeptide chain (6, 7, 48). This trimeric helical hairpin structure is thought to form at a late stage during the membrane fusion process (7). It has been proposed that there is a prehairpin intermediate in gp41-induced membrane fusion in which the N-terminal coiled coil is formed but the C-terminal helices are not packed (50). The transition from the prehairpin to the hairpin structure brings the two membranes into close proximity, driving fusion. Although much information has been gathered in recent years, we do not yet know the exact mechanisms of membrane fusion and the processes behind them.
While the FP and the PTM are essential for perturbation of the
membrane, other regions of gp41 are also involved in the interaction
and destabilization of the viral and host membranes. It was
shown recently that additional segments of the gp41 ectodomain
bind to and partition the surfaces of phospholipid model membranes,
change their conformation, and induce the formation of nonlamellar
structures, indicating that these segments may play an essential
role in the viral fusion process in addition to the other membrane-perturbing
domains (
12,
14,
26,
33,
34,
35,
38,
44,
45). These regions
might interact with biological membranes, contributing to the
merging of the viral envelope and the cell membrane. Since it
is desirable to identify critical gp41 segments that might be
responsible for the fusion process, we have studied a peptide
of 35 amino acids, analogous to residues 579 to 613 of the HXB2R
strain, comprising part of the conserved immunodominant region
of the gp41 ectodomain and the C-terminal region of the NHR
region (Fig.
1). The purposes of the present work were to study
this gp41 fragment both in aqueous solution and in the presence
of different membrane model systems composed of different phospholipid
mixtures, to evaluate its incorporation and location in membrane
model systems, and to study its effect on the integrity and
phase behavior of the membrane. The results reported here suggest
that this gp41 fragment binds and interacts with negatively
charged membranes and therefore that this region of the gp41
protein, together with the FP and PTM domains, might have a
direct role in the conformational change of the gp41 subunit
and subsequent fusion activation.

MATERIALS AND METHODS
Materials.
The HIV envelope protein gp41 fragment (Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys-Thr-Thr-Ala-Val-Pro-Trp-Asn-Ala-Ser,
with N-terminal acetylation and C-terminal amidation) corresponding
to amino acids 579 to 613 of HIV
HXB2R was obtained from Genemed
Synthesis, San Francisco, Calif. The peptide was purified by
reverse-phase high-performance liquid chromatography to >95%
purity, and its composition and molecular mass were confirmed
by amino acid analysis and mass spectroscopy. Since trifluoroacetate
has a strong infrared absorbance at approximately 1,673 cm
1,
which interferes with the characterization of the peptide amide
I band (
46), residual trifluoroacetic acid, used both in peptide
synthesis and in the high-performance liquid chromatography
mobile phase, was removed by several lyophilization-solubilization
cycles in 10 mM HCl (
53). Cholesterol (Chol), 1,2-dimyristoyl-
sn-glycero-phosphatidylcholine
(DMPC), 1,2-dimyristoyl-
d54-
sn-glycero-3-phosphocholine (DMPC
d),
1,2-dimyristoyl-
sn-glycero-phosphatidylglycerol (DMPG), 1,2-dimyristoyl-
sn-glycero-phosphatidic
acid (DMPA), egg sphingomyelin (SM), egg phosphatidylcholine
(EPC), egg phosphatidylglycerol (EPG), egg phosphatidic acid
(EPA), and bovine brain phosphatidylserine (BPS) were obtained
from Avanti Polar Lipids (Birmingham, Ala.). Lissamine rhodamine
B 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine (
N-Rh-PE),
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine
(NBD-PE), 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS),
and
p-xylene-bis-pyridiniumbromide (DPX) were obtained from
Molecular Probes (Eugene, Oreg.). Deuterium oxide (99.9% by
atom), Triton X-100, EDTA, and HEPES were purchased from Sigma
(St. Louis, Mo.). All other chemicals were commercial samples
of the highest purity available. Water was double distilled
and deionized in a Millipore system (Madrid, Spain).
Hydrophobic moments, hydrophobicity, and interfaciality.
Hydrophobic moment calculations were performed according to the method of Eisenberg et al. (17, 18), and the scale for calculating hydrophobic moments was taken from the work of Engelman et al. (19). Hydrophobicity and interfacial values, i.e., whole-residue scales for the transfer of an amino acid of an unfolded chain into the membrane hydrocarbon palisade and the membrane interface, respectively, were obtained from http://blanco.biomol.uci.edu/hydrophobicity_scales.html (49, 51).
Sample preparation.
Aliquots containing appropriate amounts of lipid in chloroform-methanol (2:1 [vol/vol]) were placed in a test tube, the solvents were removed by evaporation under a stream of O2-free nitrogen, and finally, traces of solvents were eliminated under a vacuum in the dark for more than 3 h. A preweighed amount of freeze-dried protein was suspended by the addition of an appropriate volume of buffer containing 20 mM HEPES, 50 mM NaCl, and 0.1 mM EDTA, pH 7.4 (in either D2O or H2O [see below]). The protein solution was then added to the tube containing the dried lipid to obtain a final lipid/peptide molar ratio of 15:1, unless otherwise stated, and the suspension was vortexed at about 5°C above the transition temperature of the phospholipid to obtain multilamellar vesicles. The mixture was freeze-thawed twice in order to ensure complete homogenization of the sample and a maximization of contacts between the peptide and the phospholipid and then was incubated for 10 min at 55°C with occasional vortexing. The freeze-thaw cycle was repeated again, and the suspension was then centrifuged at 12,000 x g for 15 min in order to remove any peptide that was not bound to the phospholipids in the membrane. The freeze-thaw, incubation at 55°C, and centrifugation steps were repeated once more in order to remove the unbound protein. The pellet was resuspended in either D2O or H2O buffer and used for measurements. Except for temperature studies, all data were obtained at 25°C. The phospholipid and peptide concentrations were measured by previously described methods (5, 16).
Infrared measurements.
Infrared measurements were conducted essentially as described previously (24). Fourier transform infrared spectra were obtained in a Nicolet 520 Fourier transform infrared spectrometer equipped with a deuterated triglycine sulfate detector and a sample shuttle accessory in order to average the background spectra among the sample spectra over the same time period. Subtraction of the buffer spectra, determinations of frequencies at the center of gravity, and band-narrowing strategies were applied as previously reported (24). Protein secondary structure elements were quantified from a curve-fitting analysis by band decomposition of the original amide I' band after spectral smoothing (for details, see reference 24). Briefly, for each component, the following three parameters were considered: band position, band height, and bandwidth. The number and position of component bands were obtained through deconvolution, and for decomposing the amide I' band, gaussian components were used. The curve-fitting procedure was accomplished in two steps: in the first one, the band position was fixed, allowing the width and height to approach final values, and in the second one, band positions were allowed to change. When necessary, these two steps were repeated. Band decomposition was performed with SpectraCalc software (Galactic Industries, Salem, Mass.). The fitting result was evaluated visually by overlapping the reconstituted overall curve onto the original spectrum and by examining the residual obtained by subtracting the fit from the original curve. The procedure gave differences of <2% in band areas after the artificial spectra were subjected to the curve-fitting procedure. The frequency positions of the band centers were independently evaluated by second-derivative procedures, as they were always very close to the positions found by deconvolution.
Fluorescence measurements.
Fluorescence measurements were performed essentially as described previously (12). For binding and fluorescence anisotropy experiments using the intrinsic fluorescence of Trp, small unilamellar vesicles were used (12). Large unilamellar vesicle (LUV) liposomes were used to study vesicle aggregation, lipid mixing, and leakage, and they were prepared by the extrusion method (25) by the use of polycarbonate filters with a pore size of 0.1 µm (Nuclepore, Pleasanton, Calif.). The buffer used to prepare LUV liposomes for assays of vesicle leakage also contained 25 mM ANTS and 90 mM DPX. Nonencapsulated fluorescent probes were separated from the vesicle suspension through a Sephadex G-75 filtration column (Pharmacia, Uppsala, Sweden) and were eluted at room temperature with a buffer containing 10 mM HEPES, 130 mM NaCl, and 0.1 mM EDTA, pH 7.4. Steady-state fluorescence measurements were taken as described previously (12, 24). The excitation and emission wavelengths were 295 and 359 nm, respectively, for observing peptide fluorescence. All data were corrected for background intensities and progressive dilution, but emission spectra were not corrected for photomultiplier wavelength dependence. Fluorescence anisotropies were determined according to the following equation (12):
 |
where
IVV and
IVH are the
fluorescence intensities, with the subscripts indicating the
vertical (
V) or horizontal (
H) orientation of the excitation
and emission Glan-Thompson polarizers. The instrumental factor
G (
G =
IHV/
IHH) was determined by measuring the polarized components
of fluorescence of the protein or probes with horizontally polarized
excitation. Partition coefficients were obtained according to
the following equation:
where
rL and
rW are anisotropies in the lipid and aqueous phases, respectively,
Y =
L/
W,
D = 1/[(

[
L]) 1], and
L and
W are the quantum
yields in both phases. Leakage was assayed by treating the probe-loaded
liposomes (final lipid concentration, 0.1 mM) with appropriate
amounts of peptide in a fluorometer cuvette. Changes in fluorescence
intensity were recorded at excitation and emission wavelengths
of 350 and 510 nm, respectively. One hundred percent release
was achieved by adding Triton X-100 to the cuvette at a final
concentration of 0.1% (wt/wt). Leakage was quantified on a percent
basis according to the following equation:
with
Ff being the equilibrium value of fluorescence after the peptide
addition,
F0 being the initial fluorescence of the vesicle suspension,
and
F100 being the fluorescence value after the addition of
Triton X-100. Peptide-induced vesicle lipid mixing was measured
as described previously (
43) by the use of LUV liposomes. The
concentration of both fluorescent probes, NBD-PE and
N-Rh-PE,
was 0.6%. Labeled and unlabeled LUV vesicles at a ratio of 1:9
were placed in a cuvette at a final lipid concentration of 0.1
mM and were treated with appropriate amounts of peptide. Fluorescence
was measured at excitation and emission wavelengths of 470 and
585 nm, respectively. We were not able to distinguish between
complete fusion or hemifusion due to the ability of the peptide
to induce leakage of the vesicle contents.

RESULTS
To study the ability of the gp41 peptide fragment to interact
with membranes, we obtained fluorescence anisotropy values in
the presence of phospholipid model membranes at different lipid/peptide
ratios (Fig.
2A). In the presence of model membranes, the anisotropy
values of the gp41 fragment increased upon increasing the lipid/peptide
ratio, with the limiting value being about 0.20 to 0.23, indicating
a significant motional restriction of the Trp moieties of the
peptide at a relatively high lipid/protein ratio (
28). However,
differences in the anisotropy values of the gp41 fragment were
observed when it was in the presence of the zwitterionic phospholipid
EPC and in the presence of the negatively charged phospholipids
BPS, EPG, and EPA (Fig.
2A). This was further corroborated by
a change in the emission frequency maximum of Trp, as shown
in Fig.
2B. In solution, the peptide had an absorbance maximum
at 295 nm and an emission maximum at 354 nm when excited at
the absorbance maximum, indicating that the Trp residues of
the peptide were in a hydrophilic environment. In the presence
of increasing concentrations of EPC, the emission maximum of
the Trp changed from 354 to 351 nm (Fig.
2B). However, in the
presence of increasing concentrations of negatively charged
phospholipids, the emission maximum changed from 354 to about
345 nm for EPG and from 354 to about 343 nm for EPA and BPS,
i.e., there was a difference of about 9 to 11 nm for negatively
charged phospholipids (Fig.
2B). Since upon an increase in the
environmental hydrophobicity the Trp fluorescence emission increases
and the emission maximum frequency decreases (
28), the shift
of the emission maximum of Trp by about 11 and 9 nm in the presence
of BPS and EPA liposomes and EPG liposomes, respectively, suggested
that Trp sensed a low-polarity environment (entered a hydrophobic
environment) in the presence of liposomes containing negatively
charged phospholipids, but to a much lesser extent in the presence
of zwitterionic liposomes. The peptide, having a theoretical
isoelectric point of 9.1, has a charge of about +1.91 at pH
7.4, as used in this work. EPG, EPA, and BPS, in contrast to
the zwitterionic phospholipid EPC, are negatively charged phospholipids,
so the binding force of the peptide to liposomes containing
those phospholipids had an apparently electrostatic origin.
In these experiments, the phospholipid/peptide molar ratio reached
a very high value (2,300:1), and the spectral contribution of
free peptide was negligible. The change in anisotropy values
of the Trp fluorescence of the peptide allowed us to obtain
its apparent partition coefficient,
Kp. Using a

value of 0.519
M
1 (
41), we obtained
Kp values of 1.9
x 10
2 ±
0.39
x 10
2 for EPC, 1.56
x 10
3 ± 0.4
x 10
3 for EPA, 1.55
x 10
3 ± 0.6
x 10
3 for EPG, and 3.2
x 10
3 ± 1.4
x 10
3 for BPS, indicating that the peptide was bound to the
surfaces of negatively charged phospholipid-containing model
membranes with a high affinity. Similar
Kp values have been
found for other peptides pertaining to the gp41 protein in the
presence of negatively charged phospholipid-containing membranes
(
12,
41).
In order to further explore the possible interaction of the
gp41 fragment with phospholipid model membranes, we studied
the effect of the peptide on the release of encapsulated fluorophores.
For these experiments, we used unsaturated phospholipids instead
of saturated ones because of the large amount of variability
in the basal fluorescence of the latter; nevertheless, the results
were qualitatively similar for both unsaturated and saturated
phospholipids. Figure
3 shows the results obtained with different
liposome compositions, namely EPC, EPA, EPG, BPS, and a mixture
of DMPA, DMPC, SM, and Chol at a molar ratio of 57:29:7:7. The
peptide hardly exerted any effect on liposomes made of EPC,
but significant leakage values were observed for LUVs composed
of negatively charged phospholipids, with higher values for
EPG-containing liposomes than for other liposomes (Fig.
3A).
We also studied phospholipid mixing, as shown in Fig.
3B, for
which we again found significant values for EPG-containing liposomes.
The curvature degree, i.e., the capability of obtaining nonlamellar
phases, was higher for EPG than for the other phospholipids
used in this work, which might explain why we observed lipid
mixing for EPG-containing liposomes but not for the other liposome
types studied. The peptide also induced liposome aggregation
(results not shown), as observed by the increase in light scattering
for liposomes composed of either EPG, EPA, or BPS, but not for
those composed of EPC, and only at a very low ratio of lipid
to peptide, i.e., 5:1.
The existence of structural changes induced by membrane binding
was investigated by looking at the infrared amide I' band located
between 1,700 and 1,600 cm
1 (
1). The infrared spectrum
of the amide I' region of the fully hydrated peptide in D
2O
buffer at 25°C and pH 7.4 is shown in Fig.
4A. The spectrum
was formed by different underlying components that gave rise
to a broad and asymmetric band with a maximum at about 1,642
cm
1. The maximum of the band did not change significantly
upon increasing the temperature, indicating a high degree of
conformational stability of the peptide in solution. It was
also apparent that no aggregation of the peptide took place,
since no band was observed at 1,618 to 1,622 cm
1 (
1).
In order to study the peptide when it was effectively bound
to the phospholipid membrane, we prepared all samples containing
both phospholipids and the peptide by mixing and washing the
unbound peptide as described in Materials and Methods. The infrared
spectra in the amide I' and C

O
regions of samples prepared in this way and containing the peptide
and unsaturated phospholipid, either EPC, EPA, or EPG, are shown
in Fig.
4B, C, and D, respectively. Whereas a small quantity
of peptide was bound to EPC liposomes (Fig.
4B), a significant
amount was bound to either EPA or EPG (Fig.
4C and D, respectively).
When EPC was used, the peptide was recovered almost completely
in the supernatant (not shown), indicating that the peptide
was only bound in significant amounts to negatively charged
membranes and not to zwitterionic phospholipids. As shown in
the deconvolved spectra (Fig.
4C and D, dotted lines), two bands,
at about 1,622 and 1,685 cm
1, with the former band being
more intense than the latter, can be discerned. The infrared
spectra in the amide I' and C

O
regions of samples containing the gp41 fragment and model membranes
composed of saturated phospholipids, either DMPA, DMPC
d and
DMPG at a molar ratio of 1:1, or DMPC, DMPA, SM, and Chol at
a molar ratio of 57:29:7:7, are shown in Fig.
4E, F, and G,
respectively. In all cases, a significant amount of peptide
was bound to the model membrane systems, as found previously
for membranes containing negatively charged phospholipids. The
band envelope of the amide I' band of the peptide bound to these
model membranes was different from that found for the pure peptide
in solution since, as found above, two bands, at about 1,622
and 1,685 cm
1, were well resolved (Fig.
4E, F, and G).
The frequencies of the 1,622- and 1,685-cm
1 bands and
their relative intensities indicate the presence of extended
ß-strands with strong intermolecular interactions
(
1). This was in contrast to the peptide in solution, for which
no bands at 1,622 and 1,685 cm
1 were observed (Fig.
4A).
It is interesting that the bandwidth at the half-height of the
amide I' band envelope when the peptide was bound to the membranes
increased 4 to 5 cm
1 compared to the peptide in solution.
The increase in bandwidth indicates the presence of additional
structures contributing to the broader envelope, more flexibility
of the peptide, or both.
To observe the underlying components of the broad amide I' band,
we applied self-deconvolution and derivative methods to the
original envelope (
1,
24). For the peptide in solution, we identified
different component bands at frequencies of about 1,680, 1,667,
1,652, 1,638, 1,623, and 1,605 cm
1, with the 1,638-cm
1 band being the main one (Fig.
5A). The results of the decomposition
of the amide I' band of the gp41 fragment in the presence of
three different model membrane systems, i.e., DMPA, DMPC
d and
DMPG at a molar ratio of 1:1, and DMPC, DMPA, SM, and Chol at
a molar ratio of 57:29:7:7, are shown in Fig.
5B, C, and D,
respectively, in which it is also possible to distinguish component
bands with similar frequencies to those found for the peptide
in solution, i.e., bands at about 1,680, 1,667, 1,652, 1,638,
1,623, and 1,605 cm
1. To assign the component bands to
specific structural features and to estimate the percentage
of each component, we decomposed the amide I' infrared band
as described in Materials and Methods. The most significant
difference between the amide I' band in solution and in the
presence of model membranes was the change in the intensity
of the 1,623-cm
1 band: the change was about 20% for the
peptide in solution and about 27 to 30% for the peptide in the
presence of model membranes (Table
1).
We also studied the effects of the gp41 fragment on the phase
transitions of DMPA, DMPC
d-DMPG, and a mixture of DMPC, DMPA,
SM, and Chol by infrared spectroscopy. The temperature dependence
of the CH
2 symmetric frequency of pure DMPA is shown in Fig.
6A, in which a highly cooperative change at approximately 48°C
is shown, corresponding to the gel-to-liquid crystalline phase
transition,
Tm, of the phospholipids (
30). In the presence of
the peptide, a small decrease in the gel-to-liquid crystalline
phase transition temperature was observed, but the frequencies
above and below the
Tm were similar (Fig.
6). No significant
effect was observed for the DMPC-DMPA-SM-Chol mixture in the
presence of the peptide. However, for the sample composed of
DMPC
d and DMPG, although no change was observed for the
Tm of
the mixture, the frequency above but not below the
Tm decreased,
indicating that the incorporation of the peptide increased the
proportion of
trans isomers, i.e., the hydrocarbon chains of
the phospholipids were more ordered in the presence of the peptide
below the main phase transition.
After deconvolution, the broad C

O
carbonyl band presented two components, at 1,742 and 1,727 cm
1,
which represented the
sn-1 and
sn-2 C

O
groups in their dehydrated and hydrated forms, respectively
(
30). The frequencies of these two components are not affected
by temperature, but their relative intensities change depending
on the physical state of the phospholipid bilayer (
30). For
pure DMPA, the frequency at the maximum of the C

O vibration band presented one transition at
approximately 48°C, since the 1,742-cm
1 component
had a higher intensity than the 1,727-cm
1 component below
Tm and the opposite above it (Fig.
7A). In the presence of the
gp41 fragment, the two components of the C

O carbonyl band did not change in frequency
compared to the pure phospholipid, but they changed in relative
intensity. This change in intensity gave rise to a slightly
broad transition, and significantly, the maximum of the frequency
above the
Tm was higher in the presence of the peptide than
in its absence (Fig.
7A). The same effect was observed for the
other phospholipid model membranes, DMPC
d-DMPG and DMPC-DMPA-SM-Chol,
in the presence of the gp41 fragment, i.e., there was a slightly
broad transition and a higher frequency of the maximum of the
C

O carbonyl band (Fig.
7A). The presence of the gp41 fragment did not induce any significant
differences in the frequency and width of the acyl chain CH
2 scissoring and the PO
2 double bond stretching bands appearing
at 1,468 and 1,220 cm
1, respectively, compared with the
pure phospholipids, indicating that there were no differences
in packing and hydration between the pure phospholipid and the
mixtures containing the peptide (not shown).
The temperature dependence of the maximum of the amide I' band
of the gp41 fragment in solution can be observed in Fig.
7B.
At low temperatures, the frequency maximum was about 1,639 cm
1 and increased to about 1,645 cm
1 at the highest temperature
studied. In the presence of DMPC-DMPA-SM-Chol, the frequency
was about 1,633 cm
1 at low temperatures and decreased
to about 1,625 cm
1 at higher ones, whereas in the presence
of either DMPA or DMPC
d-DMPA, it was about 1,625 cm
1 at all temperatures (Fig.
7B). It was possible to distinguish
a small increase in the intensity of the broad component appearing
at about 1,646 cm
1 for the peptide in the presence of
DMPA (Fig.
4E), but the maximum of the band remained the same
throughout all of the temperature range studied. Moreover, no
defined transitions were observed in the amide I' band which
could be concomitantly ascribed to that observed for the phospholipid
in the same sample (Fig.
7B). A similar behavior was observed
for the gp41 fragment in the presence of DMPC
d-DMPG (Fig.
4F and
7B). However, it was possible to observe a different behavior
of the peptide in the presence of the mixture composed of DMPC,
DMPA, SM, and Chol, since the maximum of the band decreased
from about 1,633 at 20°C to about 1,625 cm
1 at 70°C,
i.e., a decrease of about 9 cm
1 (Fig.
7B). This decrease
in frequency was accompanied by an increase in the intensity
of the band at about 1,622 cm
1 (Fig.
4G), indicating
an increase in the extended ß-strands upon an increase
in the temperature.

DISCUSSION
Membrane fusion reactions are involved in many important biological
processes, but strong electrostatic, hydration, and steric repulsion
forces represent large energetic barriers (
11). In biological
systems, these barriers are overcome by fusion proteins, with
the simplest membrane fusion reaction being the one produced
by the entry of enveloped viruses into host cells (
3,
15,
23).
Different structural conformational changes induced by a complex
series of protein-protein and protein-phospholipid interactions
occur in fusion proteins. However, little is known about how
these conformational changes drive membrane apposition and how
they overcome the energy barrier for membrane fusion (
29). Several
lines of evidence indicate that, in addition to classical fusion
peptides, different regions of fusion proteins, including the
HIV gp41 ectodomain, are essential for membrane fusion (
8,
12,
27,
37,
40,
45). Therefore, destabilization of the lipid bilayer
appears to be the result of the interaction of different segments
of fusion proteins with the membrane and therefore might play
a critical role in membrane fusion. Understanding the factors
that determine the specificity and stability of the metastable
(native) and stable (fusogenic) conformations is required for
an understanding of the mechanisms of viral membrane fusion
and consequent viral entry into cells (
3).
Many studies have been performed to examine the interactions of synthetic peptides mimicking the N-terminal fusion peptide and the Trp-rich proximal membrane regions of HIV gp41. However, fewer studies have been done on the interaction of other segments of the gp41 protein with membranes. We have recently shown the presence of different membranotropic regions within the gp41 ectodomain, i.e., the FP, the proximal region connecting the FP to the NHR, the PTM, and the loop (33). Moreover, an analysis of the hydrophobic and interfacial properties of the gp41 ectodomain surface (not shown) identified the already known membranotropic sequences in the gp41 ectodomain, i.e., the FP, PTM, and TM domains, and strongly suggests the presence of a stretch with interfacial hydrophobicity characteristics in the loop region. In this study, we have focused on the possible roles of the loop region in the membrane fusion process by studying a peptide which originated from this region. This 35-amino-acid peptide binds with a high affinity to negatively charged membranes, with a binding force of an apparently electrostatic origin. We previously found similar binding affinities for shorter peptides pertaining to the loop region of the gp41 protein in the presence of negatively charged phospholipid-containing model membranes (12). However, significantly, the 35-amino-acid peptide studied here is also capable of binding, although with a lower affinity, to membranes containing zwitterionic phospholipids (see above). After binding, the Trp residue resides in an environment with a low dielectric constant showing significant motional restriction, confirming that this portion of the peptide enters a hydrophobic environment but remains located at the surface of the membrane, as indicated by the absence of significant effects on the frequency of the CH2 and CD2 stretching bands of the hydrocarbon chains of the phospholipids. The strong binding of the peptide to negatively charged membranes was also confirmed by infrared spectroscopy. Only the amide I' band corresponding to the bound peptide was present in model membranes composed of negatively charged phospholipid-containing membranes, being nearly absent in model membranes formed by DMPC.
The infrared spectra of the amide I' region of the fully hydrated peptide in D2O buffer at 25 and 70°C were very similar, indicating the stability of its conformation in solution, even at high temperatures. However, when the peptide was bound to negatively charged phospholipids, its conformation changed, as the intensity of the 1,622-cm1 band, assigned to oligomeric structures (10), increased significantly. Although we have worked with phospholipid model membranes, the binding to the surface and the modulation of the phospholipid biophysical properties which take place when the peptide is bound to the membrane, i.e., partitioning into the membrane surface, aggregation, and perturbation of the bilayer architecture, may be related to the conformational changes which occur upon binding of the HIV-1 envelope glycoprotein to its receptors. The change in conformation and the possible formation of oligomeric forms in the presence of membranes may indicate the propensity of the peptide to self-assemble and suggest that these changes might be part of the structural transition that transforms gp41 from the inactive to the active state, which is most probably the dominant form during membrane fusion (9). It should be taken into account that the location of the peptide at the surface of the membrane may effectively reduce the head-group area of the phospholipid and promote the formation of nonbilayer phases (3, 12).
It has previously been suggested that hairpin folding drives the fusion reaction by initiating pore formation, but it was recently shown that fusion pore formation occurs prior to hairpin formation and that hairpins might be required for pore stabilization (31). Folding into a hairpin would bring the apposing membranes together, align the target membrane fusion domains with the transmembrane region of the viral envelope, and imply a direct interaction of the two membrane-proximal regions with their respective membrane targets (42). Since membrane fusion can be described by a succession of steps, i.e., the apposition of membranes, hemifusion of the outer leaflets, pore formation, and pore enlargement, exposed regions of the prehairpin intermediates should be responsible for the very first steps of fusion until pore initiation. Membrane fusion requires membrane destabilization, and many studies have shown that different regions of the gp41 ectodomain can significantly perturb membranes (8, 12, 27, 33, 37, 40, 45). The gp41 peptide fragment that we studied binds to, interacts with, and perturbs phospholipid model membranes, and at the same time, tends to aggregate in a membranous environment. Therefore, it would be tempting to consider that the region where this sequence resides in the native protein plays a significant role in the fusion mechanism induced by gp41. Moreover, it is supposed that the ß-sandwich structure of the gp120 inner domain is associated with the gp41 loop by specific hydrophobic interactions before gp120 interacts with its receptors (52). The loop domain of gp41, exposed after gp120 interacts with its receptor, may bind to and destabilize the host cell membrane as well as stabilize the trimeric helical hairpin after it is formed (36). It should also be noted that the energy required for the conformational changes which take place during this process may be provided by membrane binding (36). Interestingly, the study of different mutations at residues located in the loop region suggested that the loop region has a direct role in the events that take place in the membrane fusion process, possibly affecting both the formation of fusion pores and their expansion (2).
Taking into account all of these data, we have summarized in a simplified model the roles of the different membranotropic regions of gp41 (Fig. 8). Following the triggering of the envelope glycoproteins by receptors and coreceptors, the gp41 protein, which is free to oscillate, inserts the FP, most likely in the ß-sheet conformation (39), into the target membrane, joining them together. gp41 monomers interact with both membranes through the FP, the PTM, and the loop; at the same time that this interaction is taking place, it might be capable of inducing the self-assembly of gp41 oligomers at the membrane surface where the fusion site will be located (20). Even so, the two interacting faces of gp41 might interact with their adjacent membranes before or concomitantly with hairpin formation, i.e., the NHR and CHR domains have the multiple functions of binding to membranes, destabilizing them, and folding into the hairpin conformation in coordination with the loop, PTM, and FP regions (31, 42). The change in free energy associated with the structural changes taking place should be sufficient to cause lipid mixing and membrane fusion. The existence of specific lipid domains (rafts) in the membranes may be important at this step (42). In this way, the locations of complexes of gp41 would define a specific interfacial hydrophobicity distribution on the membrane surface and thus drive fusion pore enlargement (29). This interfacial hydrophobicity would also be responsible for the tendency of segments derived from rafts to oligomerize at the membrane surface (see above).
The HIV entry process is considered an attractive target for
chemotherapeutic intervention, as blocking HIV entry into target
cells leads to a suppression of viral infectivity, viral replication,
and the cytotoxicity induced by virus-cell contacts (
15,
54).
The importance of identifying drugs that prevent membrane fusion
is emphasized by the success of drug combination regimens for
the treatment of AIDS, which are mainly directed towards inverse
transcriptase and viral proteases. Several compounds are being
developed to specifically target each of the steps leading to
virus entry, and some compounds have reached early clinical
development. However, other problems, such as long-term toxicity,
cost, and the emergence of multiple drug-resistant strains,
remain far from being solved (
54). Resistance would be minimized,
though not eliminated, by the use of entry inhibitors in combination
with existing reverse transcriptase and protease inhibitors.
Therefore, the inhibition of membrane fusion by a direct action
on gp120 and/or gp41 is increasing in importance as an additional
approach either to directly combat HIV infection or to prevent
its spread. An understanding of the structural features of the
prefusogenic and fusogenic intermediates is thus very important
because gp41 appears to be an attractive drug target. The results
reported in this work sustain the notion that peptides originating
from the loop region of gp41 are capable of modifying the biophysical
properties of phospholipid membranes, providing an additional
driving force for the merging of viral and target cell membranes.
In conclusion, the data shown in this work suggest that this
region might play a significant role in the membrane fusion
mechanism induced by gp41.

ACKNOWLEDGMENTS
This work was supported by grants BMC2002-00158 (Ministerio
de Ciencia y Tecnología, Spain) and LSHB-CT-2003-503480
(European Union project "Targeting Replication and Integration
of HIV" [TRIoH]) to J.V. R.P. and M.R.M. are recipients of predoctoral
fellowships from Ministerio de Educación y Ciencia, Spain.

FOOTNOTES
* Corresponding author. Mailing address: Instituto de Biología Molecular y Celular, Universidad "Miguel Hernández," E-03202 Elche-Alicante, Spain. Phone: 34 966 658 762. Fax: 34 966 658 758. E-mail:
jvillalain{at}umh.es.


REFERENCES
1 - Arrondo, J. L., A. Muga, J. Castresana, and F. M. Goñi. 1993. Quantitative studies of the structure of proteins in solution by Fourier-transform infrared spectroscopy. Prog. Biophys. Mol. Biol. 59:23-56.[CrossRef][Medline]
2 - Bär, S., and M. Alizon. 2004. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J. Virol. 78:811-820.[Abstract/Free Full Text]
3 - Blumenthal, R., M. J. Clague, S. R. Durell, and R. M. Epand. 2003. Membrane fusion. Chem. Rev. 103:53-69.[CrossRef][Medline]
4 - Bosch, M. L., P. L. Earl, K. Fargnoli, S. Picciafuoco, F. Giombini, F. Wong-Staal, and G. Franchini. 1989. Identification of the fusion peptide of primate immunodeficiency viruses. Science 244:694-697.[Abstract/Free Full Text]
5 - Böttcher, C. S. F., C. M. Van Gent, and C. Fries. 1961. A rapid and sensitive sub-micro phosphorus determination. Anal. Chim. Acta 24:203-204.[CrossRef]
6 - Caffrey, M., M. Cai, J. Kaufman, S. J. Stahl, P. T. Wingfield, D. G. Covell, A. M. Gronenborn, and G. M. Clore. 1998. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:4572-4584.[CrossRef][Medline]
7 - Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.[CrossRef][Medline]
8 - Chan, D. C., C. T. Chutkowski, and P. S. Kim. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 95:15613-15617.[Abstract/Free Full Text]
9 - Chang, D. K., S. F. Cheng, and V. D. Trivedi. 1999. Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1. Implications on viral fusion mechanism. J. Biol. Chem. 274:5299-5309.[Abstract/Free Full Text]
10 - Chehín, R., M. Thorolfsson, P. M. Knappskog, A. Matínez, T. Flatmark, J. L. R. Arrondo, and A. Muga. 1998. Domain structure and stability of human phenylalanine hydroxylase inferred from infrared spectroscopy. FEBS Lett. 422:225-230.[CrossRef][Medline]
11 - Chernomordik, L. V., and M. M. Kozlov. 2003. Protein-lipid interplay in fusion and fission of biological membranes. Annu. Rev. Biochem. 72:175-207.[CrossRef][Medline]
12 - Contreras, L. M., F. J. Aranda, F. Gavilanes, J. M. González-Ros, and J. Villalaín. 2001. Structure and interaction with membrane model systems of a peptide derived from the major epitope region of HIV protein gp41: implications on viral fusion mechanism. Biochemistry 40:3196-3207.[CrossRef][Medline]
13 - Dimitrov, A. S., X. Xiao, D. S. Dimitrov, and R. Blumenthal. 2000. Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J. Biol. Chem. 276:30335-30341.
14 - Dimitrov, A. S., S. S. Rawat, S. Jiang, and R. Blumenthal. 2003. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry 42:14150-14158.[CrossRef][Medline]
15 - Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.[CrossRef][Medline]
16 - Edelhoch, H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6:1948-1954.[CrossRef][Medline]
17 - Eisenberg, D., R. M. Weiss, and T. C. Terwilliger. 1982. The helical hydrophobic moment: a measure of the amphiphilicity of a helix. Nature 299:371-374.[CrossRef][Medline]
18 - Eisenberg, D., E. Schwarz, M. Komaromy, and R. Wall. 1984. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 179:125-142.[CrossRef][Medline]
19 - Engelman, D. M., T. A. Steitz, and A. Goldman. 1986. Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins. Annu. Rev. Biophys. Chem. 15:321-353.[CrossRef][Medline]
20 - Follis, K. E., S. J. Larson, M. Lu, and J. H. Nunberg. 2002. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J. Virol. 76:7356-7362.[Abstract/Free Full Text]
21 - Gallaher, W. R. 1987. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 50:327-328.[CrossRef][Medline]
22 - Gallaher, W. R., J. M. Ball, R. F. Garry, M. C. Griffin, and R. C. Montelaro. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retrovir. 5:431-440.[Medline]
23 - Gallo, S. A., C. M. Finnegan, M. Viard, Y. Raviv, A. Dimitrov, S. S. Rawat, A. Puri, S. Durell, and R. Blumenthal. 2003. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614:36-50.[Medline]
24 - Giudici, M., R. Pascual, L. de la Canal, K. Pfüller, U. Pfüller, and J. Villalaín. 2003. Interaction of viscotoxins A3 and B with membrane model systems: implications to their mechanism of action. Biophys. J. 85:971-981.[Medline]
25 - Hope, M. J., M. B. Bally, G. Webb, and P. R. Cullis. 1985. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812:55-65.[CrossRef]
26 - Kliger, Y., S. G. Peisajovich, R. Blumenthal, and Y. Shai. 2000. Membrane-induced conformational change during the activation of HIV-1 gp41. J. Mol. Biol. 301:905-914.[CrossRef][Medline]
27 - Kliger, Y., S. A. Gallo, S. G. Peisajovich, I. Muñoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai. 2001. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 276:1391-1397.[Abstract/Free Full Text]
28 - Lakowicz, J. R. 1999. Principles of fluorescence spectroscopy, 2nd ed. Plenum Press, New York, N.Y.
29 - Lentz, B. R., V. Malinin, M. E. Haque, and K. Evans. 2000. Protein machines and lipid assemblies: current views of cell membrane fusion. Curr. Opin. Struct. Biol. 10:607-615.[CrossRef][Medline]
30 - Mantsch, H. H., and E. N. McElhaney. 1991. Phospholipid phase transitions in model and biological membranes as studied by infrared spectroscopy. Chem. Phys. Lipids 57:213-226.[CrossRef][Medline]
31 - Markosyan, R. M., F. S. Cohen, and G. B. Melikyan. 2003. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol. Biol. Cell 14:926-938.[Abstract/Free Full Text]
32 - Markovic, I., and K. A. Clouse. 2004. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr. HIV Res. 2:223-234.[CrossRef][Medline]
33 - Moreno, M. R., R. Pascual, and J. Villalaín. 2004. Identification of membrane-active regions of the HIV-1 envelope glycoprotein gp41 using a 15-mer gp41-peptide scan. Biochim. Biophys. Acta 1661:97-105.[Medline]
34 - Peisajovich, S. G., R. F. Epand, M. Pritsker, Y. Shai, and R. M. Epand. 2000. The polar region consecutive to the fusion peptide participates in membrane fusion. Biochemistry 39:1826-1833.[CrossRef][Medline]
35 - Peisajovich, S. G., and Y. Shai. 2001. SIV gp41 binds to membranes both in the monomeric and trimeric states: consequences for the neuropathology and inhibition of HIV infection. J. Mol. Biol. 311:249-254.[CrossRef][Medline]
36 - Peisajovich, S. G., L. Blank, R. F. Epand, R. M. Epand, and Y. Shai. 2003. On the interaction between gp41 and membranes: the immunodominant loop stabilizes gp41 helical hairpin conformation. J. Mol. Biol. 326:1489-1501.[CrossRef][Medline]
37 - Poumbourios, P., W. el Ahmar, D. A. McPhee, and B. E. Kemp. 1995. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J. Virol. 69:1209-1218.[Abstract]
38 - Sackett, K., and Y. Shai. 2002. The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. Biochemistry 41:4678-4685.[CrossRef][Medline]
39 - Sackett, K., and Y. Shai. 2003. How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J. Mol. Biol. 333:47-58.[CrossRef][Medline]
40 - Salzwedel, K., J. T. West, and E. Hunter. 1999. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73:2469-2480.[Abstract/Free Full Text]
41 - Santos, N. C., M. Prieto, and M. A. Castanho. 1998. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence study. Biochemistry 37:8674-8682.[CrossRef][Medline]
42 - Shnaper, S., K. Sackett, S. A. Gallo, R. Blumenthal, and Y. Shai. 2004. The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J. Biol. Chem. 279:18526-18534.[Abstract/Free Full Text]
43 - Struck, D. K., D. Hoekstra, and R. E. Pagano. 1981. Use of resonance energy transfer to monitor membrane fusion. Biochemistry 20:4093-4099.[CrossRef][Medline]
44 - Suárez, T., S. Nir, F. M. Goñi, A. Sáez-Cirión, and J. L. Nieva. 2000. The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Lett. 477:145-149.[CrossRef][Medline]
45 - Suárez, T., W. R. Gallaher, A. Agirre, F. M. Goñi, and J. L. Nieva. 2000. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J. Virol. 74:8038-8047.[Abstract/Free Full Text]
46 - Surewicz, W. K., H. H. Mantsch, and D. Chapman. 1993. Determination of protein secondary structure by Fourier transform infrared spectroscopy: a critical assessment. Biochemistry 32:389-394.[CrossRef][Medline]
47 - Turner, B. G., and M. F. Summers. 1999. Structural biology of HIV. J. Mol. Biol. 285:1-32.[CrossRef][Medline]
48 - Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wimley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.[CrossRef][Medline]
49 - White, S. H., and W. C. Wimley. 1999. Membrane protein folding and stability: physical principles. Annu. Rev. Biophys. Biomol. Struct. 28:319-365.[CrossRef][Medline]
50 - Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.[Abstract/Free Full Text]
51 - Wimley, W. C., and S. H. White. 1996. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat. Struct. Biol. 3:842-848.[CrossRef][Medline]
52 - York, J., and J. H. Nunberg. 2004. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J. Virol. 78:4921-4926.[Abstract/Free Full Text]
53 - Zhang, Y. P., R. N. A. H. Lewis, R. S. Hodges, and R. N. McElhaney. 1992. FTIR spectroscopic studies of the conformation and amide hydrogen exchange of a peptide model of the hydrophobic transmembrane alpha-helices of membrane proteins. Biochemistry 31:11572-11578.[CrossRef][Medline]
54 - Zwick, M. B., E. O. Saphire, and D. R. Burton. 2004. gp41: HIV's shy protein. Nat. Med. 10:133-134.[CrossRef][Medline]
Journal of Virology, April 2005, p. 5142-5152, Vol. 79, No. 8
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.8.5142-5152.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Lu, L., Zhu, Y., Huang, J., Chen, X., Yang, H., Jiang, S., Chen, Y.-H.
(2008). Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process: INTERACTION WITH gp41 FUSION CORE. J. Biol. Chem.
283: 16723-16731
[Abstract]
[Full Text]
-
Perez-Berna, A. J., Guillen, J., Moreno, M. R., Bernabeu, A., Pabst, G., Laggner, P., Villalain, J.
(2008). Identification of the Membrane-active Regions of Hepatitis C Virus p7 Protein: BIOPHYSICAL CHARACTERIZATION OF THE LOOP REGION. J. Biol. Chem.
283: 8089-8101
[Abstract]
[Full Text]